Articles Accepted

Development and validation of a new HPLC bio analytical internal standard method for the analysis of Favipiravir in human plasma
by Dr. PHANI R S CH, 19 Aug 2020

Favipiravir (FVPR) is an influenza drug and also investigated on Ebola virus, Lassa virus, and now COVID-19. A new sensitive and rapid HPLC method was developed for the determination of FVPR in plasma. ; it was validated according to ICH and FDA guidelines. The HPLC analysis was performed on the Agilent 1100 series HPLC with Quaternary G1311 A pump Hypersil, C18 Column (250 X 4.6 mm, 5μ) column, with a mixture of Water and Methanol in the ratio of 15:85 (v/v) as the mobile phase, at the flow rate of 1.5 mL/min. The detection was performed at the wavelength (λ) of 244 nm, and the retention time of FVPR is 13.01 min. The total run time was 20.0 min. The calibration plot gave linear relationship over the concentration range of 20–140 ng/ml. The repeatability testing of the method showed that the method is precise within the acceptable limits. RSD% of the determination of precision was

Current Issue
November 2020
Quick Contact